<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur J Pediatr</journal-id><journal-title>European Journal of Pediatrics</journal-title><issn pub-type="ppub">0340-6199</issn><issn pub-type="epub">1432-1076</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17287932</article-id><article-id pub-id-type="pmc">1802727</article-id><article-id pub-id-type="publisher-id">419</article-id><article-id pub-id-type="doi">10.1007/s00431-007-0419-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>The probiotic <italic>Escherichia coli</italic> strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Henker</surname><given-names>Jobst</given-names></name><address><phone>+49-351-4583449</phone><fax>+49-351-4585358</fax><email>Jobst.Henker@uniklinikum-dresden.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Laass</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Blokhin</surname><given-names>Boris M.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bolbot</surname><given-names>Yuriy K.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Maydannik</surname><given-names>Vitaliy G.</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Elze</surname><given-names>Martina</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wolff</surname><given-names>Corinna</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schulze</surname><given-names>Jürgen</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><aff id="Aff1"><label>1</label>Department of Paediatrics, University Hospital Carl-Gustav-Carus, Fetscherstrasse 74, 01307 Dresden, Germany </aff><aff id="Aff2"><label>2</label>Outpatient Paediatrics, Russian State Medical University, Moscow, Russia </aff><aff id="Aff3"><label>3</label>Paediatrics No. 2, Dnepropetrovsk State Medical Academy, Dnepropetrovsk, Ukraine </aff><aff id="Aff4"><label>4</label>Paediatrics No. 4, City Paediatric Clinical Hospital No. 6, National Medical University, O. O. Bogomolets, Kyiv, Ukraine </aff><aff id="Aff5"><label>5</label>ClinResearch, Institute for Monitoring, Data Management, Biometrics and Medical Writing, Cologne, Germany </aff><aff id="Aff6"><label>6</label>Ardeypharm, Herdecke, Germany </aff></contrib-group><pub-date pub-type="epub"><day>8</day><month>2</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>4</month><year>2007</year></pub-date><volume>166</volume><issue>4</issue><fpage>311</fpage><lpage>318</lpage><history><date date-type="received"><day>26</day><month>10</month><year>2006</year></date><date date-type="rev-recd"><day>20</day><month>12</month><year>2006</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2006</year></date></history><permissions><copyright-statement>© Springer-Verlag 2007</copyright-statement></permissions><abstract><p><offsets xml_i="3876" xml_f="4266" txt_i="11" txt_f="401">In most cases, acute diarrhoea will become self-limiting during the first few days after onset. For young children, however, health risks may develop when the disease lasts longer than 3 days. The purpose of the present trial was to determine whether the stool frequency of infants and toddlers suffering from acute diarrhoea could be normalised more quickly by administering the probiotic </offsets><italic><offsets xml_i="4274" xml_f="4290" txt_i="401" txt_f="417">Escherichia coli</offsets></italic><offsets xml_i="4299" xml_f="4580" txt_i="417" txt_f="695"> Nissle 1917 (EcN) solution than by administering a placebo. The safety of EcN were also assessed. A total of 113 children (aged 2–47 months) with acute diarrhoea (&gt; three watery or loose stools in 24 h) were randomised to either a group receiving the probiotic EcN suspension (</offsets><italic><offsets xml_i="4588" xml_f="4589" txt_i="695" txt_f="696">n</offsets></italic><offsets xml_i="4598" xml_f="4650" txt_i="696" txt_f="748"> = 55) or a group receiving the placebo suspension (</offsets><italic><offsets xml_i="4658" xml_f="4659" txt_i="748" txt_f="749">n</offsets></italic><offsets xml_i="4668" xml_f="4795" txt_i="749" txt_f="876"> = 58) in a confirmative, double-blind clinical trial. Depending on the age of patients, 1–3 ml per day of verum suspension (10</offsets><sup><offsets xml_i="4800" xml_f="4801" txt_i="876" txt_f="877">8</offsets></sup><offsets xml_i="4807" xml_f="5287" txt_i="877" txt_f="1357"> viable EcN cells per millilitre) or placebo were administered orally. The causes of the diarrhoea were viral rather than bacterial, but they were mainly unspecific infections. The median onset of treatment response (reduction of daily stool frequency to ≤ three watery or loose stools over at least 2 consecutive days) occurred more rapidly in the children receiving the EcN solution (2.5 days) than in those receiving the placebo (4.8 days), a significant difference (2.3 days; </offsets><italic><offsets xml_i="5295" xml_f="5296" txt_i="1357" txt_f="1358">p</offsets></italic><offsets xml_i="5305" xml_f="5379" txt_i="1358" txt_f="1432"> = 0.0007). The number of patients showing a response was clearly higher (</offsets><italic><offsets xml_i="5387" xml_f="5388" txt_i="1432" txt_f="1433">p</offsets></italic><offsets xml_i="5397" xml_f="5654" txt_i="1433" txt_f="1687"> &lt; 0.0001) in the EcN group (52/55; 94.5%) than in the placebo group (39/58; 67.2%). EcN was found to be safe and well-tolerated, and it showed a significant superiority compared to the placebo in the treatment of acute diarrhoea in infants and toddlers.</offsets></p><sec><title><offsets xml_i="5670" xml_f="5703" txt_i="1688" txt_f="1721">Electronic supplementary material</offsets></title><p><offsets xml_i="5714" xml_f="5871" txt_i="1722" txt_f="1879">The online version of this article (doi:http://dx.doi.org/10.1007/s00431-007-0419-x) contains supplementary material, which is available to authorized users.</offsets></p></sec></abstract><kwd-group><title>Keywords</title><kwd>Acute diarrhoea</kwd><kwd>EcN</kwd><kwd><italic>Escherichia coli</italic> Nissle 1917</kwd><kwd>Infants</kwd><kwd>Probiotic</kwd><kwd>Toddlers</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© Springer-Verlag 2007</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="6325" xml_f="6337" txt_i="1888" txt_f="1900">Introduction</offsets></title><p><offsets xml_i="6348" xml_f="6622" txt_i="1901" txt_f="2175">Probiotics are non-pathogenic microorganisms – mostly of human origin – which confer health benefits to the host when administered in adequate amounts. They are considered to be a safe and effective part of the first-line therapy for acute diarrhoea in children and adults [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="6655" xml_f="6657" txt_i="2175" txt_f="2177">12</offsets></xref><offsets xml_i="6664" xml_f="6939" txt_i="2177" txt_f="2452">]. In addition, probiotics are able to prevent or improve not only gastrointestinal diseases such as inflammatory bowel disease, irritable bowel syndrome, infectious gastroenteritis or diverticular disease of the colon, but also to act in the prevention of allergic diseases.</offsets></p><p><offsets xml_i="6946" xml_f="7141" txt_i="2453" txt_f="2648">Various probiotics are commercially available in, for example, Europe, the USA and Japan where they are marketed as functional foods or probiotic drugs. To date, lactobacilli, bifidobacteria and </offsets><italic><offsets xml_i="7149" xml_f="7172" txt_i="2648" txt_f="2671">Saccharomyces boulardii</offsets></italic><offsets xml_i="7181" xml_f="7261" txt_i="2671" txt_f="2751"> are the most commonly marketed probiotic active substances. Certain strains of </offsets><italic><offsets xml_i="7269" xml_f="7285" txt_i="2751" txt_f="2767">Escherichia coli</offsets></italic><offsets xml_i="7294" xml_f="7377" txt_i="2767" txt_f="2850"> are also available in some European countries, the best known example of which is </offsets><italic><offsets xml_i="7385" xml_f="7392" txt_i="2850" txt_f="2857">E. coli</offsets></italic><offsets xml_i="7401" xml_f="7427" txt_i="2857" txt_f="2883"> strain Nissle 1917 (EcN).</offsets></p><p><offsets xml_i="7434" xml_f="7579" txt_i="2884" txt_f="3029">EcN is marketed as a probiotic drug in two galenic presentations for oral use: enteric-coated capsules and a suspension in which 1 ml contains 10</offsets><sup><offsets xml_i="7584" xml_f="7585" txt_i="3029" txt_f="3030">8</offsets></sup><offsets xml_i="7591" xml_f="7671" txt_i="3030" txt_f="3110"> viable EcN cells. While capsules are mostly used in adults (e.g. Kruis et al. [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="7703" xml_f="7704" txt_i="3110" txt_f="3111">8</offsets></xref><offsets xml_i="7711" xml_f="7808" txt_i="3111" txt_f="3208">]), the use of the suspension form is the most reasonable form in neonates, infants and toddlers.</offsets></p><p><offsets xml_i="7815" xml_f="8040" txt_i="3209" txt_f="3434">The purpose of the present trial was to examine the efficacy and safety of an EcN suspension administered to infants and toddlers suffering from acute diarrhoea of different causes in terms of normalising the stool frequency.</offsets></p></sec><sec id="Sec2" sec-type="materials|methods"><title><offsets xml_i="8101" xml_f="8122" txt_i="3436" txt_f="3457">Materials and methods</offsets></title><p><offsets xml_i="8133" xml_f="8812" txt_i="3458" txt_f="4137">Infants and toddlers treated for acute diarrhoea in the paediatric outpatient wards of 11 centres between February and April 2005 were eligible for enrollment in this study. This was a multicentre, prospective, confirmative, randomised, double-blind, placebo-controlled, parallel group clinical trial of phase III. It was carried out in accordance with the requirements of Good Clinical Practice and the Revised Declaration of Helsinki. The study was approved by the Independent Ethics Committee (IEC) of the Federal Agency of Drugs Quality Control, Moscow, Russia, and by the IEC of the State Enterprise Centre of Immunobiological Medicines at the Ministry of Health of Ukraine.</offsets></p><p><offsets xml_i="8819" xml_f="9281" txt_i="4138" txt_f="4597">Acute diarrhoea was defined as more than three watery-to-loose stools per day from an acute episode of non-bloody diarrhoea which did not persist longer than 3 successive days. For reasons of comparability, one of the exclusion criteria was a higher grade of dehydration (loss of body weight &gt;5%; hydration status was surveyed, rehydration was not implemented in low-grade dehydration); the most important inclusion and exclusion criteria are listed in Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="9315" xml_f="9316" txt_i="4597" txt_f="4598">1</offsets></xref><offsets xml_i="9323" xml_f="9460" txt_i="4598" txt_f="4735">. The participant was assessed until ascertainment of response, 10 days at maximum. An overview of the study design is presented in Fig. </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="9492" xml_f="9493" txt_i="4735" txt_f="4736">1</offsets></xref><offsets xml_i="9500" xml_f="9627" txt_i="4736" txt_f="4863">. A stool sample was taken at both the beginning and end of the study and checked for the presence of the following pathogens: </offsets><italic><offsets xml_i="9635" xml_f="9645" txt_i="4863" txt_f="4873">Salmonella</offsets></italic><offsets xml_i="9654" xml_f="9656" txt_i="4873" txt_f="4875">, </offsets><italic><offsets xml_i="9664" xml_f="9677" txt_i="4875" txt_f="4888">Campylobacter</offsets></italic><offsets xml_i="9686" xml_f="9688" txt_i="4888" txt_f="4890">, </offsets><italic><offsets xml_i="9696" xml_f="9704" txt_i="4890" txt_f="4898">Yersinia</offsets></italic><offsets xml_i="9713" xml_f="9715" txt_i="4898" txt_f="4900">, </offsets><italic><offsets xml_i="9723" xml_f="9730" txt_i="4900" txt_f="4907">E. coli</offsets></italic><offsets xml_i="9739" xml_f="9766" txt_i="4907" txt_f="4934"> (ETEC, EPEC, EIEC, EHEC), </offsets><italic><offsets xml_i="9774" xml_f="9782" txt_i="4934" txt_f="4942">Shigella</offsets></italic><offsets xml_i="9791" xml_f="9793" txt_i="4942" txt_f="4944">, </offsets><italic><offsets xml_i="9801" xml_f="9822" txt_i="4944" txt_f="4965">Entamoeba histolytica</offsets></italic><offsets xml_i="9831" xml_f="9833" txt_i="4965" txt_f="4967">, </offsets><italic><offsets xml_i="9841" xml_f="9863" txt_i="4967" txt_f="4989">Cryptosporidium parvum</offsets></italic><offsets xml_i="9872" xml_f="9909" txt_i="4989" txt_f="5026"> and Rota-, Adeno- and Noroviruses. 
</offsets><table-wrap id="Tab1"><label><offsets xml_i="9938" xml_f="9945" txt_i="5026" txt_f="5033">Table 1</offsets></label><caption><p><offsets xml_i="9965" xml_f="9997" txt_i="5033" txt_f="5065">Inclusion and exclusion criteria</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="10063" xml_f="10081" txt_i="5066" txt_f="5084">Inclusion criteria</offsets></th><th><offsets xml_i="10090" xml_f="10108" txt_i="5084" txt_f="5102">Exclusion criteria</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="10141" xml_f="10181" txt_i="5102" txt_f="5139">Age &lt;4 years at the time of enrolment</offsets></td><td><offsets xml_i="10190" xml_f="10230" txt_i="5140" txt_f="5177">Dehydration (&gt;5% loss of body weight)</offsets></td></tr><tr><td><offsets xml_i="10248" xml_f="10374" txt_i="5178" txt_f="5304">More than three watery or loose non-bloody stools in a 24-h period that had not persisted for more than three consecutive days</offsets></td><td><offsets xml_i="10383" xml_f="10422" txt_i="5305" txt_f="5344">Participation in another clinical trial</offsets></td></tr><tr><td><offsets xml_i="10440" xml_f="10478" txt_i="5345" txt_f="5383">Signed informed consent by the parents</offsets></td><td><offsets xml_i="10487" xml_f="10544" txt_i="5384" txt_f="5441">Intake of EcN within the past 3 months prior to enrolment</offsets></td></tr><tr><td></td><td><offsets xml_i="10571" xml_f="10737" txt_i="5443" txt_f="5609">Intake of food supplements or drugs which contain living microorganisms or their metabolic products or components within 7 days prior to enrolment or during the trial</offsets></td></tr><tr><td></td><td><offsets xml_i="10764" xml_f="10790" txt_i="5611" txt_f="5637">Other antidiarrhoeal drugs</offsets></td></tr><tr><td></td><td><offsets xml_i="10817" xml_f="10828" txt_i="5639" txt_f="5650">Antibiotics</offsets></td></tr><tr><td></td><td><offsets xml_i="10855" xml_f="10886" txt_i="5652" txt_f="5683">Breast-feeding, Premature birth</offsets></td></tr><tr><td></td><td><offsets xml_i="10913" xml_f="10982" txt_i="5685" txt_f="5754">Severe or chronic disease of the bowel or severe concomitant diseases</offsets></td></tr></tbody></table></table-wrap><fig id="Fig1"><label><offsets xml_i="11043" xml_f="11049" txt_i="5755" txt_f="5761">Fig. 1</offsets></label><caption><p><offsets xml_i="11069" xml_f="11083" txt_i="5761" txt_f="5775">Study design. </offsets><italic><offsets xml_i="11091" xml_f="11103" txt_i="5775" txt_f="5787">*Final visit</offsets></italic><offsets xml_i="11112" xml_f="11197" txt_i="5787" txt_f="5872"> Duration of treatment, which was until ascertainment of response, 10 days at maximum</offsets></p></caption><graphic position="anchor" xlink:href="431_2007_419_Fig1_HTML" id="MO1"></graphic></fig></p><p><offsets xml_i="11306" xml_f="11700" txt_i="5874" txt_f="6268">The parents were asked to maintain a daily record (diary) containing information on the number of stools, stool consistency, admixtures of blood or mucus, frequency of vomiting, abdominal pain and cramps and fluid intake as well as concomitant medication and general state of health. An assessment of general health was also documented during each control visit by the investigator and parents.</offsets></p><p><offsets xml_i="11707" xml_f="11927" txt_i="6269" txt_f="6489">The randomisation schedule was generated by means of SAS, ver. 9.1 (SAS Institute, Cary, N.C.) based on seed values dependent on a random number generator. The method of randomly permuted blocks was used (block size: 4).</offsets></p><sec id="Sec3"><title><offsets xml_i="11953" xml_f="11969" txt_i="6490" txt_f="6506">Study medication</offsets></title><p><offsets xml_i="11980" xml_f="12092" txt_i="6507" txt_f="6619">The drug being studied (verum) is a commercially available suspension for oral use that contains non-pathogenic </offsets><italic><offsets xml_i="12100" xml_f="12107" txt_i="6619" txt_f="6626">E. coli</offsets></italic><offsets xml_i="12116" xml_f="12196" txt_i="6626" txt_f="6706"> strain Nissle 1917 (Mutaflor suspension; Ardeypharm, Herdecke, Germany, with 10</offsets><sup><offsets xml_i="12201" xml_f="12202" txt_i="6706" txt_f="6707">8</offsets></sup><offsets xml_i="12208" xml_f="12628" txt_i="6707" txt_f="7127"> viable microorganisms per millilitre). As placebo, we administered an identical preparation consisting of a suspension devoid of the active substance. In accordance with good clinical practice (GCP), identical containers were used in order to guarantee a concealed random allocation both to the parents and the study personnel involved. Depending on the age, daily doses of the study medication (EcN or placebo) were: 
</offsets><table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td><offsets xml_i="12702" xml_f="12720" txt_i="7127" txt_f="7142">Infants &lt;1 year</offsets></td><td><offsets xml_i="12729" xml_f="12744" txt_i="7143" txt_f="7158">1 ml once daily</offsets></td></tr><tr><td><offsets xml_i="12762" xml_f="12785" txt_i="7159" txt_f="7182">Toddlers ≥1 to ≤3 years</offsets></td><td><offsets xml_i="12794" xml_f="12810" txt_i="7183" txt_f="7199">1 ml twice daily</offsets></td></tr><tr><td><offsets xml_i="12828" xml_f="12857" txt_i="7200" txt_f="7223">Toddlers &gt;3 to &lt;4 years</offsets></td><td><offsets xml_i="12866" xml_f="12888" txt_i="7224" txt_f="7246">1 ml three times daily</offsets></td></tr></tbody></table></table-wrap></p><p><offsets xml_i="12934" xml_f="13202" txt_i="7248" txt_f="7516">The parents received a diary in which the intake of the trial medication was documented. The investigator checked the entries for completeness and plausibility. The compliance was also evaluated by comparing the amount of trial medication handed out with that returns.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="13234" xml_f="13241" txt_i="7518" txt_f="7525">Outcome</offsets></title><p><offsets xml_i="13252" xml_f="13668" txt_i="7526" txt_f="7942">The primary effect criterion was the time to response. Treatment response was defined as a reduction in stool frequency to ≤ three watery or loose stools in 24 h over a period of at least 2 consecutive days. Secondary effect criteria included the response rate, stool consistency, abdominal pain and cramps, body temperature, frequency of vomiting, occurrence of adverse events and tolerance to the study medication.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="13700" xml_f="13720" txt_i="7944" txt_f="7964">Statistical analysis</offsets></title><p><offsets xml_i="13731" xml_f="13911" txt_i="7965" txt_f="8145">The study was conducted according to a three-stage group sequential test design (O’Brien/Fleming type) with possible sample size adaptation after the two planned interim analyses [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="13943" xml_f="13944" txt_i="8145" txt_f="8146">9</offsets></xref><offsets xml_i="13951" xml_f="14616" txt_i="8146" txt_f="8811">]. A time-to-response analysis was performed (Kaplan-Meier method; log-rank test to test the superiority of EcN compared to placebo; overall type-I error rate α = 0.025; one-sided). The response rates were also computed and compared between treatment groups by means of Fisher’s exact test (one-sided; exploratory). The intention-to-treat (ITT) data set included all randomised patients who took at least one dose of study medication (primary analysis), whereas patients with major protocol violations were excluded from the per-protocol (PP) analysis. The analysis sets were defined in a blind review of the data. The sample size was estimated prospectively using </offsets><sc><offsets xml_i="14620" xml_f="14627" txt_i="8811" txt_f="8818">ADDPLAN</offsets></sc><offsets xml_i="14632" xml_f="14895" txt_i="8818" txt_f="9081"> ver. 3.0. An independent data monitoring committee (IDMC) was responsible for reviewing the results of the interim analyses and giving recommendations. Two interim analyses were performed, resulting in continuation of the study with the pre-planned sample sizes.</offsets></p></sec></sec><sec id="Sec6" sec-type="results"><title><offsets xml_i="14952" xml_f="14959" txt_i="9084" txt_f="9091">Results</offsets></title><sec id="Sec7"><title><offsets xml_i="14989" xml_f="15002" txt_i="9092" txt_f="9105">Baseline data</offsets></title><p><offsets xml_i="15013" xml_f="15274" txt_i="9106" txt_f="9367">A total of 113 infants and toddlers between 2 and 47 months of age with acute diarrhoea were admitted to the trial. All patients were Caucasian. The patients were randomly allocated to either the EcN group (55 patients) or the placebo group (58 patients) (Fig. </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="15306" xml_f="15307" txt_i="9367" txt_f="9368">2</offsets></xref><offsets xml_i="15314" xml_f="15445" txt_i="9368" txt_f="9499">). No relevant differences between the groups were observed in terms of gender, age, height, weight and BMI of the patients (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="15479" xml_f="15480" txt_i="9499" txt_f="9500">2</offsets></xref><offsets xml_i="15487" xml_f="15769" txt_i="9500" txt_f="9782">). The vast majority of patients had an average body development and a good nutritional status, but reduced appetite was reported. There were also no differences in systolic and diastolic blood pressure, heart rate and body temperature between the two treatment groups at baseline.
</offsets><fig id="Fig2"><label><offsets xml_i="15791" xml_f="15797" txt_i="9782" txt_f="9788">Fig. 2</offsets></label><caption><p><offsets xml_i="15817" xml_f="15844" txt_i="9788" txt_f="9815">Diagram of participant flow</offsets></p></caption><graphic position="anchor" xlink:href="431_2007_419_Fig2_HTML" id="MO2"></graphic></fig><table-wrap id="Tab2"><label><offsets xml_i="15975" xml_f="15982" txt_i="9816" txt_f="9823">Table 2</offsets></label><caption><p><offsets xml_i="16002" xml_f="16044" txt_i="9823" txt_f="9865">Baseline data for the two treatment groups</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2"></th><th><offsets xml_i="16131" xml_f="16136" txt_i="9866" txt_f="9871">EcN (</offsets><italic><offsets xml_i="16144" xml_f="16145" txt_i="9871" txt_f="9872">n</offsets></italic><offsets xml_i="16154" xml_f="16160" txt_i="9872" txt_f="9878"> = 55)</offsets></th><th><offsets xml_i="16169" xml_f="16178" txt_i="9878" txt_f="9887">Placebo (</offsets><italic><offsets xml_i="16186" xml_f="16187" txt_i="9887" txt_f="9888">n</offsets></italic><offsets xml_i="16196" xml_f="16202" txt_i="9888" txt_f="9894"> = 58)</offsets></th></tr></thead><tbody><tr><td colspan="2"><offsets xml_i="16247" xml_f="16259" txt_i="9894" txt_f="9906">Male gender </offsets></td><td><offsets xml_i="16268" xml_f="16278" txt_i="9907" txt_f="9917">32 (58.2%)</offsets></td><td><offsets xml_i="16287" xml_f="16297" txt_i="9918" txt_f="9928">32 (55.2%)</offsets></td></tr><tr><td colspan="2"><offsets xml_i="16327" xml_f="16339" txt_i="9929" txt_f="9941">Age (median)</offsets></td><td><offsets xml_i="16348" xml_f="16357" txt_i="9942" txt_f="9951">21 months</offsets></td><td><offsets xml_i="16366" xml_f="16375" txt_i="9952" txt_f="9961">23 months</offsets></td></tr><tr><td colspan="2"><offsets xml_i="16405" xml_f="16421" txt_i="9962" txt_f="9978">Height (median) </offsets></td><td><offsets xml_i="16430" xml_f="16435" txt_i="9979" txt_f="9984">83 cm</offsets></td><td><offsets xml_i="16444" xml_f="16449" txt_i="9985" txt_f="9990">83 cm</offsets></td></tr><tr><td colspan="2"><offsets xml_i="16479" xml_f="16494" txt_i="9991" txt_f="10006">Weight (median)</offsets></td><td><offsets xml_i="16503" xml_f="16510" txt_i="10007" txt_f="10014">12.7 kg</offsets></td><td><offsets xml_i="16519" xml_f="16526" txt_i="10015" txt_f="10022">12.6 kg</offsets></td></tr><tr><td colspan="2"><offsets xml_i="16556" xml_f="16569" txt_i="10023" txt_f="10036">BMI (median) </offsets></td><td><offsets xml_i="16578" xml_f="16587" txt_i="10037" txt_f="10046">17.4 kg/m</offsets><sup><offsets xml_i="16592" xml_f="16593" txt_i="10046" txt_f="10047">2</offsets></sup></td><td><offsets xml_i="16608" xml_f="16617" txt_i="10048" txt_f="10057">17.2 kg/m</offsets><sup><offsets xml_i="16622" xml_f="16623" txt_i="10057" txt_f="10058">2</offsets></sup></td></tr><tr><td colspan="2"><offsets xml_i="16659" xml_f="16685" txt_i="10059" txt_f="10085">Mean duration of diarrhoea</offsets></td><td><offsets xml_i="16694" xml_f="16702" txt_i="10086" txt_f="10094">1.4 days</offsets></td><td><offsets xml_i="16711" xml_f="16719" txt_i="10095" txt_f="10103">1.6 days</offsets></td></tr><tr><td colspan="2"><offsets xml_i="16749" xml_f="16769" txt_i="10104" txt_f="10124">Mean stool frequency</offsets></td><td><offsets xml_i="16778" xml_f="16789" txt_i="10125" txt_f="10136">5.0 per day</offsets></td><td><offsets xml_i="16798" xml_f="16809" txt_i="10137" txt_f="10148">5.1 per day</offsets></td></tr><tr><td rowspan="5"><offsets xml_i="16839" xml_f="16894" txt_i="10149" txt_f="10204">Possible causes for the current acute diarrhoea episode</offsets></td><td><offsets xml_i="16903" xml_f="16932" txt_i="10205" txt_f="10234">Previous antibiotic treatment</offsets></td><td><offsets xml_i="16941" xml_f="16949" txt_i="10235" txt_f="10243">2 (3.6%)</offsets></td><td><offsets xml_i="16958" xml_f="16966" txt_i="10244" txt_f="10252">4 (6.9%)</offsets></td></tr><tr><td><offsets xml_i="16984" xml_f="17001" txt_i="10253" txt_f="10270">Virus infections </offsets></td><td><offsets xml_i="17010" xml_f="17020" txt_i="10271" txt_f="10281">16 (29.1%)</offsets></td><td><offsets xml_i="17029" xml_f="17039" txt_i="10282" txt_f="10292">19 (32.8%)</offsets></td></tr><tr><td><offsets xml_i="17057" xml_f="17077" txt_i="10293" txt_f="10313">Bacterial infections</offsets></td><td><offsets xml_i="17086" xml_f="17095" txt_i="10314" txt_f="10323">9 (16.4%)</offsets></td><td><offsets xml_i="17104" xml_f="17112" txt_i="10324" txt_f="10332">4 (6.8%)</offsets></td></tr><tr><td><offsets xml_i="17130" xml_f="17152" txt_i="10333" txt_f="10355">Unspecified infections</offsets></td><td><offsets xml_i="17161" xml_f="17171" txt_i="10356" txt_f="10366">25 (45.5%)</offsets></td><td><offsets xml_i="17180" xml_f="17190" txt_i="10367" txt_f="10377">29 (50.0%)</offsets></td></tr><tr><td><offsets xml_i="17208" xml_f="17220" txt_i="10378" txt_f="10390">Other causes</offsets></td><td><offsets xml_i="17229" xml_f="17237" txt_i="10391" txt_f="10399">3 (5.5%)</offsets></td><td><offsets xml_i="17246" xml_f="17254" txt_i="10400" txt_f="10408">2 (3.4%)</offsets></td></tr></tbody></table></table-wrap></p><p><offsets xml_i="17300" xml_f="17806" txt_i="10410" txt_f="10916">There was no difference in the duration of the current acute diarrhoea episode between patients in the EcN group and placebo group (EcN: 1.4 ± 0.6 days, mean: 1.0 days; placebo: 1.6 ± 0.6 days, mean: 2.0 days). The number of infections during the past 12 months was ≤ five in 55/55 patients (100%) of the EcN group and 56/58 patients (96.6%) of the placebo group. Infections as a cause of the acute diarrhoea were more often viral than bacterial. However, unspecific infections were the most common (Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="17840" xml_f="17841" txt_i="10916" txt_f="10917">2</offsets></xref><offsets xml_i="17848" xml_f="18081" txt_i="10917" txt_f="11150">). The number and proportion of patients with pathogenic microorganisms were slightly higher in the EcN group (27/55 patients) than in the placebo group (21/58 patients) at baseline. This difference was not statistically significant.</offsets></p></sec><sec id="Sec8"><title><offsets xml_i="18113" xml_f="18126" txt_i="11152" txt_f="11165">Data analyses</offsets></title><p><offsets xml_i="18137" xml_f="18301" txt_i="11166" txt_f="11330">All efficacy analyses were originally designed to be performed on both the ITT and PP data sets. However, as the ITT and PP data sets were identical in this study (</offsets><italic><offsets xml_i="18309" xml_f="18310" txt_i="11330" txt_f="11331">n</offsets></italic><offsets xml_i="18319" xml_f="18430" txt_i="11331" txt_f="11442"> = 113 patients), only the ITT data are evaluated here. All safety analyses were performed on the ITT data set.</offsets></p></sec><sec id="Sec9"><title><offsets xml_i="18462" xml_f="18479" txt_i="11444" txt_f="11461">Primary objective</offsets></title><p><offsets xml_i="18490" xml_f="18788" txt_i="11462" txt_f="11760">The median time to response was 2.5 days in the EcN group and 4.8 days in the placebo group, i.e. treatment with EcN shortened the duration of diarrhoea by 2.3 days. Statistical testing revealed that the EcN treatment was significantly superior to that of the placebo in terms of time to response (</offsets><italic><offsets xml_i="18796" xml_f="18797" txt_i="11760" txt_f="11761">p</offsets></italic><offsets xml_i="18806" xml_f="18825" txt_i="11761" txt_f="11780"> = 0.0007; overall </offsets><italic><offsets xml_i="18833" xml_f="18834" txt_i="11780" txt_f="11781">p</offsets></italic><offsets xml_i="18843" xml_f="18893" txt_i="11781" txt_f="11831"> value of the group sequential test design) (Fig. </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="18925" xml_f="18926" txt_i="11831" txt_f="11832">3</offsets></xref><offsets xml_i="18933" xml_f="19030" txt_i="11832" txt_f="11929">). Analysis by centre showed no difference in the number of responders between treatment groups.
</offsets><fig id="Fig3"><label><offsets xml_i="19052" xml_f="19058" txt_i="11929" txt_f="11935">Fig. 3</offsets></label><caption><p><offsets xml_i="19078" xml_f="19139" txt_i="11935" txt_f="11996">Time-to-response curves: Kaplan-Meier analysis (ITT analysis)</offsets></p></caption><graphic position="anchor" xlink:href="431_2007_419_Fig3_HTML" id="MO3"></graphic></fig></p><p><offsets xml_i="19248" xml_f="19437" txt_i="11998" txt_f="12187">In total, diarrhoea was stopped in 52/55 patients (94.5%) in the EcN group and 39/58 patients (67.2%) in the placebo group within 10 days. Fourteen patients dropped out of the trials (EcN, </offsets><italic><offsets xml_i="19445" xml_f="19446" txt_i="12187" txt_f="12188">n</offsets></italic><offsets xml_i="19455" xml_f="19470" txt_i="12188" txt_f="12203"> = 1; placebo, </offsets><italic><offsets xml_i="19478" xml_f="19479" txt_i="12203" txt_f="12204">n</offsets></italic><offsets xml_i="19488" xml_f="19649" txt_i="12204" txt_f="12365"> = 13) because of unsuccessful therapy. The diarrhoea did not cease within 10 days of treatment in two patients of the EcN and six patients of the placebo group.</offsets></p></sec><sec id="Sec10"><title><offsets xml_i="19682" xml_f="19702" txt_i="12367" txt_f="12387">Secondary objectives</offsets></title><p><offsets xml_i="19713" xml_f="19829" txt_i="12388" txt_f="12504">An exploratory comparison showed a significant difference in the number of responders between the treatment groups (</offsets><italic><offsets xml_i="19837" xml_f="19838" txt_i="12504" txt_f="12505">p</offsets></italic><offsets xml_i="19847" xml_f="20152" txt_i="12505" txt_f="12807"> &lt; 0.0001; ratio of rates: 1.406; 95%CI: 1.162–1.701). A cumulative presentation of the number of responders on each study day showed a difference between EcN- and placebo-treated patients starting on day 3 [EcN 34/55 (61.8%) vs. placebo 24/58 (41.4%); ratio of rates: 1.494; 95%CI: 1.032–2.163] (Fig. </offsets><xref rid="Fig4" ref-type="fig"><offsets xml_i="20184" xml_f="20185" txt_i="12807" txt_f="12808">4</offsets></xref><offsets xml_i="20192" xml_f="20470" txt_i="12808" txt_f="13086">). The difference increased until day 5 [EcN 45/55 (81.8%) vs. placebo 30/58 (51.7%); ratio of rates: 1.582; 95%CI: 1.198–2.089] and then decreased slightly from day 6 to the end of study [EcN 52/55 (94.5%) vs. placebo 39/58 (67.2%); ratio of rates: 1.406; 95%CI: 1.162–1.701).
</offsets><fig id="Fig4"><label><offsets xml_i="20492" xml_f="20498" txt_i="13086" txt_f="13092">Fig. 4</offsets></label><caption><p><offsets xml_i="20518" xml_f="20580" txt_i="13092" txt_f="13154">Response rates among the patients receiving the EcN solution (</offsets><italic><offsets xml_i="20588" xml_f="20589" txt_i="13154" txt_f="13155">n</offsets></italic><offsets xml_i="20598" xml_f="20618" txt_i="13155" txt_f="13175"> = 55) and placebo (</offsets><italic><offsets xml_i="20626" xml_f="20627" txt_i="13175" txt_f="13176">n</offsets></italic><offsets xml_i="20636" xml_f="20673" txt_i="13176" txt_f="13213"> = 58) during the course of the study</offsets></p></caption><graphic position="anchor" xlink:href="431_2007_419_Fig4_HTML" id="MO4"></graphic></fig></p><p><offsets xml_i="20782" xml_f="21199" txt_i="13215" txt_f="13632">Prior to the treatment regimen, almost no infant had a normal stool consistency. During the course of the study the patients of the EcN group showed a more pronounced improvement than their counterparts in the placebo group. The same trend was observed for the disappearance of abdominal pain (28/30 EcN patients vs. 24/33 placebo patients) and abdominal cramps (17/18 EcN patients vs. 21/26 placebo patients) (Table </offsets><xref rid="Tab3" ref-type="table"><offsets xml_i="21233" xml_f="21234" txt_i="13632" txt_f="13633">3</offsets></xref><offsets xml_i="21241" xml_f="21245" txt_i="13633" txt_f="13637">). 
</offsets><table-wrap id="Tab3"><label><offsets xml_i="21274" xml_f="21281" txt_i="13637" txt_f="13644">Table 3</offsets></label><caption><p><offsets xml_i="21301" xml_f="21340" txt_i="13644" txt_f="13683">Improvement of symptoms after treatment</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="21406" xml_f="21407" txt_i="13684" txt_f="13685"> </offsets></th><th><offsets xml_i="21416" xml_f="21423" txt_i="13685" txt_f="13692">EcN (%)</offsets></th><th><offsets xml_i="21432" xml_f="21443" txt_i="13692" txt_f="13703">Placebo (%)</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="21476" xml_f="21500" txt_i="13703" txt_f="13727">Normal stool consistency</offsets></td><td><offsets xml_i="21509" xml_f="21513" txt_i="13728" txt_f="13732">78.4</offsets></td><td><offsets xml_i="21522" xml_f="21526" txt_i="13733" txt_f="13737">40.5</offsets></td></tr><tr><td><offsets xml_i="21544" xml_f="21561" txt_i="13738" txt_f="13755">No abdominal pain</offsets></td><td><offsets xml_i="21570" xml_f="21574" txt_i="13756" txt_f="13760">93.3</offsets></td><td><offsets xml_i="21583" xml_f="21587" txt_i="13761" txt_f="13765">72.7</offsets></td></tr><tr><td><offsets xml_i="21605" xml_f="21624" txt_i="13766" txt_f="13785">No abdominal cramps</offsets></td><td><offsets xml_i="21633" xml_f="21637" txt_i="13786" txt_f="13790">94.4</offsets></td><td><offsets xml_i="21646" xml_f="21650" txt_i="13791" txt_f="13795">80.8</offsets></td></tr></tbody></table></table-wrap></p><p><offsets xml_i="21696" xml_f="22412" txt_i="13797" txt_f="14513">In addition, the general state of health, as assessed by the investigator during clinical examinations or by the parents by means of the diary, of the patients in the EcN group improved more clearly than that of the patients in the placebo group (data not shown). Body temperature showed an almost identical decrease over time in both treatment groups (EcN: −0.5 ± 0.4°C; placebo: −0.4 ± 0.5°C). The number of vomiting episodes was very small at baseline in all patients and decreased to 0% in both groups. In principle, body weight and the status of dehydration did not show any changes from baseline to the end of study in either treatment group. Only one patient in the placebo group experienced mild dehydration.</offsets></p><p><offsets xml_i="22419" xml_f="22820" txt_i="14514" txt_f="14915">From baseline to study termination, pathogenic microorganisms disappeared in a similar number of patients in both treatment groups (14/27 patients in the EcN group and 12/21 patients in the placebo group). In the patients who were free from infectious agents at baseline, pathogenic microorganisms were detected at the end of study in 3/28 and 6/37 patients in the EcN and placebo group, respectively.</offsets></p></sec><sec id="Sec11"><title><offsets xml_i="22853" xml_f="22875" txt_i="14917" txt_f="14939">Tolerance to treatment</offsets></title><p><offsets xml_i="22886" xml_f="23744" txt_i="14940" txt_f="15798">The study medication was well tolerated. Only 2/55 patients (3.6%) in the EcN group and 2/58 patients (3.4%) in the placebo group experienced one adverse event (AE) each. These were rhinitis and abdominal pain in the EcN-treated patients and two cases of acute otitis media in the patients receiving the placebo. According to the European Medicines Agency (EMEA) classification, none of these AEs are rated as “serious” or “severe” (regulatory guidance CPMP/ICH/377/95). The two placebo-treated patients with otitis media were removed from the study due to the AE being intolerable. For the two AEs in patients receiving the EcN treatment, complete recovery was documented. According to the parents, tolerance to treatment was slightly better in the EcN group than in the placebo group, whereas no notable difference was observed by the investigators (Table </offsets><xref rid="Tab4" ref-type="table"><offsets xml_i="23778" xml_f="23779" txt_i="15798" txt_f="15799">4</offsets></xref><offsets xml_i="23786" xml_f="23790" txt_i="15799" txt_f="15803">). 
</offsets><table-wrap id="Tab4"><label><offsets xml_i="23819" xml_f="23826" txt_i="15803" txt_f="15810">Table 4</offsets></label><caption><p><offsets xml_i="23846" xml_f="23896" txt_i="15810" txt_f="15860">Tolerance to treatment in the two treatment groups</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th><offsets xml_i="23962" xml_f="23963" txt_i="15861" txt_f="15862"> </offsets></th><th colspan="4"><offsets xml_i="23984" xml_f="24003" txt_i="15862" txt_f="15881">Assessed by parents</offsets></th><th colspan="4"><offsets xml_i="24024" xml_f="24049" txt_i="15881" txt_f="15906">Assessed by investigators</offsets></th></tr><tr><th><offsets xml_i="24067" xml_f="24068" txt_i="15906" txt_f="15907"> </offsets></th><th colspan="2"><offsets xml_i="24089" xml_f="24092" txt_i="15907" txt_f="15910">EcN</offsets></th><th colspan="2"><offsets xml_i="24113" xml_f="24120" txt_i="15910" txt_f="15917">Placebo</offsets></th><th colspan="2"><offsets xml_i="24141" xml_f="24144" txt_i="15917" txt_f="15920">EcN</offsets></th><th colspan="2"><offsets xml_i="24165" xml_f="24172" txt_i="15920" txt_f="15927">Placebo</offsets></th></tr></thead><tbody><tr><td><offsets xml_i="24205" xml_f="24214" txt_i="15927" txt_f="15936">Very good</offsets></td><td colspan="2"><offsets xml_i="24235" xml_f="24247" txt_i="15937" txt_f="15949">11/55 (20.0)</offsets><sup><offsets xml_i="24252" xml_f="24253" txt_i="15949" txt_f="15950">a</offsets></sup></td><td colspan="2"><offsets xml_i="24280" xml_f="24290" txt_i="15951" txt_f="15961">4/58 (6.9)</offsets></td><td colspan="2"><offsets xml_i="24311" xml_f="24321" txt_i="15962" txt_f="15972">5/55 (9.1)</offsets></td><td colspan="2"><offsets xml_i="24342" xml_f="24352" txt_i="15973" txt_f="15983">4/58 (6.9)</offsets></td></tr><tr><td><offsets xml_i="24370" xml_f="24374" txt_i="15984" txt_f="15988">Good</offsets></td><td colspan="2"><offsets xml_i="24395" xml_f="24407" txt_i="15989" txt_f="16001">44/55 (80.0)</offsets></td><td colspan="2"><offsets xml_i="24428" xml_f="24440" txt_i="16002" txt_f="16014">53/58 (91.4)</offsets></td><td colspan="2"><offsets xml_i="24461" xml_f="24473" txt_i="16015" txt_f="16027">50/55 (90.9)</offsets></td><td colspan="2"><offsets xml_i="24494" xml_f="24506" txt_i="16028" txt_f="16040">53/58 (91.4)</offsets></td></tr><tr><td><offsets xml_i="24524" xml_f="24528" txt_i="16041" txt_f="16045">Poor</offsets></td><td colspan="2"><offsets xml_i="24549" xml_f="24559" txt_i="16046" txt_f="16056">0/55 (0.0)</offsets></td><td colspan="2"><offsets xml_i="24580" xml_f="24590" txt_i="16057" txt_f="16067">1/58 (1.7)</offsets></td><td colspan="2"><offsets xml_i="24611" xml_f="24621" txt_i="16068" txt_f="16078">0/55 (0.0)</offsets></td><td colspan="2"><offsets xml_i="24642" xml_f="24652" txt_i="16079" txt_f="16089">1/58 (1.7)</offsets></td></tr></tbody></table><table-wrap-foot><p><sup><offsets xml_i="24703" xml_f="24704" txt_i="16090" txt_f="16091">a</offsets></sup><offsets xml_i="24710" xml_f="24744" txt_i="16091" txt_f="16125">Percentage is given in parenthesis</offsets></p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12" sec-type="discussion"><title><offsets xml_i="24840" xml_f="24850" txt_i="16129" txt_f="16139">Discussion</offsets></title><p><offsets xml_i="24861" xml_f="25354" txt_i="16140" txt_f="16633">The aim of this multicentre, prospective, confirmative, randomised, double-blind, placebo-controlled clinical trial of phase III was to investigate the therapeutic efficacy and safety of orally administered EcN in treating acute diarrhoea in infants and toddlers. The results showed that EcN was superior to the placebo in terms of both time to response and response rate. The difference in median duration of diarrhoea – 2.3 days – was statistically significant and also clinically important.</offsets></p><p><offsets xml_i="25361" xml_f="25987" txt_i="16634" txt_f="17260">Acute diarrhoea in children is very often self-limiting within a few days. However, toddlers and young infants are in danger of developing dehydration and a deteriorating general health. Therefore, a fast-tracking antidiarrhoeal treatment would be beneficial. Several investigations have been carried out with probiotics for the treatment of acute gastroenteritis, and different meta-analyses and systematic reviews have been published in this field. All of these have demonstrated the efficacy of probiotics in treating or preventing diarrhoea. On average, the treatment of diarrhoea with lactobacilli, bifidobacteria and/or </offsets><italic><offsets xml_i="25995" xml_f="26007" txt_i="17260" txt_f="17272">S. boulardii</offsets></italic><offsets xml_i="26016" xml_f="26075" txt_i="17272" txt_f="17331"> shortened the duration of diarrhoea by only 0.5–1.5 days [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="26107" xml_f="26108" txt_i="17331" txt_f="17332">4</offsets></xref><offsets xml_i="26115" xml_f="26117" txt_i="17332" txt_f="17334">, </offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="26150" xml_f="26152" txt_i="17334" txt_f="17336">12</offsets></xref><offsets xml_i="26159" xml_f="26161" txt_i="17336" txt_f="17338">, </offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="26194" xml_f="26196" txt_i="17338" txt_f="17340">14</offsets></xref><offsets xml_i="26203" xml_f="26205" txt_i="17340" txt_f="17342">, </offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="26238" xml_f="26240" txt_i="17342" txt_f="17344">18</offsets></xref><offsets xml_i="26247" xml_f="26249" txt_i="17344" txt_f="17346">, </offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="26282" xml_f="26284" txt_i="17346" txt_f="17348">19</offsets></xref><offsets xml_i="26291" xml_f="26293" txt_i="17348" txt_f="17350">].</offsets></p><p><offsets xml_i="26300" xml_f="26539" txt_i="17351" txt_f="17590">Szajewska and Mrukowicz reviewed ten randomised, double-blind, placebo-controlled studies and concluded that the administration of probiotics led to a substantial reduction in the duration of acute diarrhoeal symptoms: an average of 20 h [</offsets><xref ref-type="bibr" rid="CR18"><offsets xml_i="26572" xml_f="26574" txt_i="17590" txt_f="17592">18</offsets></xref><offsets xml_i="26581" xml_f="26746" txt_i="17592" txt_f="17757">]. Moreover, a meta-analysis of nine clinical trials conducted by D’Souza et al. demonstrated that probiotics effectively prevented antibiotic-associated diarrhoea [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="26778" xml_f="26779" txt_i="17757" txt_f="17758">4</offsets></xref><offsets xml_i="26786" xml_f="27050" txt_i="17758" txt_f="18022">]. The work of van Niel et al. included nine randomised controlled studies with lactobacilli in acute infectious diarrhoea in children. In these studies, the duration of diarrhoea was significantly reduced by an average of 0.7 days along with the stool frequency [</offsets><xref ref-type="bibr" rid="CR19"><offsets xml_i="27083" xml_f="27085" txt_i="18022" txt_f="18024">19</offsets></xref><offsets xml_i="27092" xml_f="27305" txt_i="18024" txt_f="18237">]. Most recently, McFarland et al. examined the efficacy of probiotics in paediatric diarrhoea by analysing 39 randomised, controlled and blinded clinical trials comprising a total of 41 probiotic treatment arms [</offsets><xref ref-type="bibr" rid="CR12"><offsets xml_i="27338" xml_f="27340" txt_i="18237" txt_f="18239">12</offsets></xref><offsets xml_i="27347" xml_f="27555" txt_i="18239" txt_f="18447">]. Of these, 32 (78%) reported efficacy. The latest meta-analysis of 39 trials by Sazawal et al. showed that probiotics prevented acute diarrhea, with a risk reduction among children off 57% (range: 35–71%) [</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="27588" xml_f="27590" txt_i="18447" txt_f="18449">14</offsets></xref><offsets xml_i="27597" xml_f="27920" txt_i="18449" txt_f="18772">]. Diarrhoea is one of the best-studied indications for probiotics, and treatment with EcN has been found to stop acute diarrhoea more rapidly than other probiotics. The efficacy of EcN was confirmed by a second multicentre, prospective, randomised, double-blind, placebo-controlled phase III study conducted by our group [</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="27952" xml_f="27953" txt_i="18772" txt_f="18773">7</offsets></xref><offsets xml_i="27960" xml_f="28138" txt_i="18773" txt_f="18951">]. In that study, children with prolonged diarrhoea treated with EcN showed a more rapid onset of response to treatment than those treated with placebo (median: 2.4 vs. 5.7 days;</offsets><italic><offsets xml_i="28146" xml_f="28148" txt_i="18951" txt_f="18953"> p</offsets></italic><offsets xml_i="28157" xml_f="28399" txt_i="18953" txt_f="19192"> &lt; 0.0001). There was also a remarkable difference in the response rates, as determined on days 14 (EcN: 93.3%; placebo: 65.8%) and 21 (EcN: 98.7%; placebo: 71.1%), thus showing a statistically significant superiority of EcN on both days (</offsets><italic><offsets xml_i="28407" xml_f="28408" txt_i="19192" txt_f="19193">p</offsets></italic><offsets xml_i="28417" xml_f="28431" txt_i="19193" txt_f="19207"> = 0.0017 and </offsets><italic><offsets xml_i="28439" xml_f="28440" txt_i="19207" txt_f="19208">p</offsets></italic><offsets xml_i="28449" xml_f="28476" txt_i="19208" txt_f="19232"> &lt; 0.001, respectively).</offsets></p><p><offsets xml_i="28483" xml_f="28861" txt_i="19233" txt_f="19611">In the present trial, high initial response rates in both groups represent the spontaneous healing known for acute gastroenteritis. The superiority of the EcN treatment became increasingly noticeable from 3. The healing process was markedly faster in the EcN-treated patients than in the patients receiving placebo, a result which underlines the high efficacy of this probiotic.</offsets></p><p><offsets xml_i="28868" xml_f="29241" txt_i="19612" txt_f="19985">The relatively high number of children with unspecific diarrhoea corresponds quite well to the frequent failure to detect the responsible pathogen in routine analyses. This is the reason why the results of this study are not helpful in answering the question whether EcN is more efficient in bacterial or viral diarrhea. This question should be addressed by future studies.</offsets></p><p><offsets xml_i="29248" xml_f="29709" txt_i="19986" txt_f="20447">In the present study, EcN was safe and well-tolerated. There was no difference between the EcN and placebo treatments in terms of AEs, body weight, stool examinations and the assessment of tolerance. This result is in accordance with experience from clinical trials in premature and fullterm newborns where EcN was not only very safe but improved the microbial intestinal milieu of the treated infants and reduced the risk of acquiring pathogens early in life [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="29741" xml_f="29742" txt_i="20447" txt_f="20448">3</offsets></xref><offsets xml_i="29749" xml_f="29751" txt_i="20448" txt_f="20450">, </offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="29784" xml_f="29786" txt_i="20450" txt_f="20452">10</offsets></xref><offsets xml_i="29793" xml_f="29795" txt_i="20452" txt_f="20454">, </offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="29828" xml_f="29830" txt_i="20454" txt_f="20456">11</offsets></xref><offsets xml_i="29837" xml_f="30042" txt_i="20456" txt_f="20661">]. It has also been shown that prolonged colonisation with EcN protected infants at an age of 6–12 months from flatulence, diarrhoea or constipation when given immediately on the first 5 days after birth [</offsets><xref ref-type="bibr" rid="CR16"><offsets xml_i="30075" xml_f="30077" txt_i="20661" txt_f="20663">16</offsets></xref><offsets xml_i="30084" xml_f="30086" txt_i="20663" txt_f="20665">].</offsets></p><p><offsets xml_i="30093" xml_f="30315" txt_i="20666" txt_f="20888">Our understanding of the effects of probiotics and their numerous modes of action has grown substantially in recent years. With regard to gastroenteritis, probiotics may improve symptoms by several mechanisms, including: 
</offsets><list list-type="bullet"><list-item><p><offsets xml_i="30354" xml_f="30496" txt_i="20888" txt_f="21030">competition with pathogens (for adherence to intestinal epithelium, for growth and survival in the gut) and inhibition of pathogen overgrowth;</offsets></p></list-item><list-item><p><offsets xml_i="30526" xml_f="30603" txt_i="21031" txt_f="21108">secretion of bacteriostatic/bactericidal peptides (e.g. colicins, microcins);</offsets></p></list-item><list-item><p><offsets xml_i="30633" xml_f="30717" txt_i="21109" txt_f="21193">enforcement of intestinal barrier function and reduction of microbial translocation;</offsets></p></list-item><list-item><p><offsets xml_i="30747" xml_f="30884" txt_i="21194" txt_f="21331">modulation of immune responses (local and/or systemic, e.g. stimulation of secretion of IgA by lymphocytes and defensins by enterocytes).</offsets></p></list-item></list></p><p><offsets xml_i="30914" xml_f="30968" txt_i="21333" txt_f="21387">All of these mechanisms of action have been shown for </offsets><italic><offsets xml_i="30976" xml_f="30983" txt_i="21387" txt_f="21394">E. coli</offsets></italic><offsets xml_i="30992" xml_f="31127" txt_i="21394" txt_f="21529"> strain Nissle 1917. The antagonistic activity of EcN against pathogens has been demonstrated in vitro in animal models and in humans [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="31159" xml_f="31160" txt_i="21529" txt_f="21530">1</offsets></xref><offsets xml_i="31167" xml_f="31169" txt_i="21530" txt_f="21532">, </offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="31202" xml_f="31204" txt_i="21532" txt_f="21534">10</offsets></xref><offsets xml_i="31211" xml_f="31213" txt_i="21534" txt_f="21536">, </offsets><xref ref-type="bibr" rid="CR13"><offsets xml_i="31246" xml_f="31248" txt_i="21536" txt_f="21538">13</offsets></xref><offsets xml_i="31255" xml_f="31257" txt_i="21538" txt_f="21540">, </offsets><xref ref-type="bibr" rid="CR17"><offsets xml_i="31290" xml_f="31292" txt_i="21540" txt_f="21542">17</offsets></xref><offsets xml_i="31299" xml_f="31393" txt_i="21542" txt_f="21636">]. In a pig model of intestinal infection, EcN was able to prevent acute secretory diarrhoea [</offsets><xref ref-type="bibr" rid="CR15"><offsets xml_i="31426" xml_f="31428" txt_i="21636" txt_f="21638">15</offsets></xref><xref ref-type="bibr" rid="CR2"><offsets xml_i="31467" xml_f="31468" txt_i="21638" txt_f="21639">2</offsets></xref><offsets xml_i="31475" xml_f="31477" txt_i="21639" txt_f="21641">, </offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="31509" xml_f="31510" txt_i="21641" txt_f="21642">5</offsets></xref><offsets xml_i="31517" xml_f="31519" txt_i="21642" txt_f="21644">, </offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="31551" xml_f="31552" txt_i="21644" txt_f="21645">6</offsets></xref><offsets xml_i="31559" xml_f="31621" txt_i="21645" txt_f="21707">], EcN exerts an intense immunomodulatory effect in children [</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="31653" xml_f="31654" txt_i="21707" txt_f="21708">3</offsets></xref><offsets xml_i="31661" xml_f="31663" txt_i="21708" txt_f="21710">, </offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="31696" xml_f="31698" txt_i="21710" txt_f="21712">11</offsets></xref><offsets xml_i="31705" xml_f="31893" txt_i="21712" txt_f="21900">]. Here, EcN was found to stimulate the production of antibodies of mucosa-associated B lymphocytes and the systemic production of antibodies (IgM, IgA) in premature and fullterm children.</offsets></p></sec><sec id="Sec13"><title><offsets xml_i="31926" xml_f="31936" txt_i="21902" txt_f="21912">Conclusion</offsets></title><p><offsets xml_i="31947" xml_f="32175" txt_i="21913" txt_f="22141">In summary, EcN showed a significant superiority to placebo in the treatment of acute diarrhoea in infants and toddlers. EcN treatment also improved the general state of health and its administration was safe and well tolerated.</offsets></p></sec><sec sec-type="supplementary-material"><title><offsets xml_i="32231" xml_f="32264" txt_i="22143" txt_f="22176">Electronic supplementary material</offsets></title><supplementary-material id="N0x1a580e0N0x2f33d28" content-type="local-data"><p><offsets xml_i="32351" xml_f="32411" txt_i="22177" txt_f="22237">Below is the link to the electronic supplementary material 
</offsets></p><media xlink:href="431_2007_419_MOESM1_ESM.doc" id="MOESM1" mimetype="application" mime-subtype="msword"><caption><p><offsets xml_i="32532" xml_f="32564" txt_i="22238" txt_f="22270">Statistical analysis (DOC 31 kb)</offsets></p></caption></media></supplementary-material></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Altenhoefer</surname><given-names>A</given-names></name><name><surname>Oswald</surname><given-names>S</given-names></name><name><surname>Sonnenborn</surname><given-names>U</given-names></name><name><surname>Enders</surname><given-names>C</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name><name><surname>Hacker</surname><given-names>J</given-names></name><name><surname>Oelschlaeger</surname><given-names>TA</given-names></name></person-group><article-title>The probiotic <italic>Escherichia coli</italic> strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens</article-title><source>FEMS Immunol Med Microbiol</source><year>2004</year><volume>40</volume><fpage>223</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1016/S0928-8244(03)00368-7</pub-id></citation><citation citation-type="display-unstructured">Altenhoefer A, Oswald S, Sonnenborn U, Enders C, Schulze J, Hacker J, Oelschlaeger TA (2004) The probiotic Escherichia coli strain Nissle 1917 interferes with invasion of human intestinal epithelial cells by different enteroinvasive bacterial pathogens. FEMS Immunol Med Microbiol 40:223–229 <pub-id pub-id-type="pmid">15039098</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blum-Oehler</surname><given-names>G</given-names></name><name><surname>Oswald</surname><given-names>S</given-names></name><name><surname>Eiteljörge</surname><given-names>K</given-names></name><name><surname>Sonnenborn</surname><given-names>U</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name><name><surname>Kruis</surname><given-names>W</given-names></name><name><surname>Hacker</surname><given-names>J</given-names></name></person-group><article-title>Development of strain-specific PCR reactions for the detection of the probiotic <italic>Escherichia coli</italic> strain Nissle 1917 in fecal samples</article-title><source>Res Microbiol</source><year>2003</year><volume>154</volume><fpage>59</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/S0923-2508(02)00007-4</pub-id></citation><citation citation-type="display-unstructured">Blum-Oehler G, Oswald S, Eiteljörge K, Sonnenborn U, Schulze J, Kruis W, Hacker J (2003) Development of strain-specific PCR reactions for the detection of the probiotic Escherichia coli strain Nissle 1917 in fecal samples. Res Microbiol 154:59–66 <pub-id pub-id-type="pmid">12576161</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cukrowska</surname><given-names>B</given-names></name><name><surname>Lodinova-Zadnikova</surname><given-names>R</given-names></name><name><surname>Enders</surname><given-names>C</given-names></name><name><surname>Sonnenborn</surname><given-names>U</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name><name><surname>Tlaskalova-Hogenova</surname><given-names>H</given-names></name></person-group><article-title>Specific proliferative and antibody response of premature infants to intestinal colonization with nonpathogenic probiotic <italic>E. coli</italic> strain Nissle 1917</article-title><source>Scand J Immunol</source><year>2002</year><volume>55</volume><fpage>204</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1046/j.1365-3083.2002.01005.x</pub-id></citation><citation citation-type="display-unstructured">Cukrowska B, Lodinova-Zadnikova R, Enders C, Sonnenborn U, Schulze J, Tlaskalova-Hogenova H (2002) Specific proliferative and antibody response of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol 55:204–209 <pub-id pub-id-type="pmid">11896937</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>D’Souza</surname><given-names>AL</given-names></name><name><surname>Rajkumar</surname><given-names>C</given-names></name><name><surname>Cooke</surname><given-names>J</given-names></name><name><surname>Bulpitt</surname><given-names>CJ</given-names></name></person-group><article-title>Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis</article-title><source>BMJ</source><year>2002</year><volume>324</volume><fpage>1361</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1136/bmj.324.7350.1361</pub-id></citation><citation citation-type="display-unstructured">D’Souza AL, Rajkumar C, Cooke J, Bulpitt CJ (2002) Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 324:1361–1366 <pub-id pub-id-type="pmid">12052801</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grozdanov</surname><given-names>L</given-names></name><name><surname>Zähringer</surname><given-names>U</given-names></name><name><surname>Blum-Oehler</surname><given-names>G</given-names></name><name><surname>Brade</surname><given-names>L</given-names></name><name><surname>Henne</surname><given-names>A</given-names></name><name><surname>Knirel</surname><given-names>YA</given-names></name><name><surname>Schombel</surname><given-names>U</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name><name><surname>Sonnenborn</surname><given-names>U</given-names></name><name><surname>Gottschalk</surname><given-names>G</given-names></name><name><surname>Hacker</surname><given-names>J</given-names></name><name><surname>Rietschel</surname><given-names>ET</given-names></name><name><surname>Dobrindt</surname><given-names>U</given-names></name></person-group><article-title>A single nucleotide exchange in the <italic>wzy</italic> gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of<italic> Escherichia coli</italic> strain Nissle 1917</article-title><source>J Bacteriol</source><year>2002</year><volume>184</volume><fpage>5912</fpage><lpage>5925</lpage><pub-id pub-id-type="doi">10.1128/JB.184.21.5912-5925.2002</pub-id></citation><citation citation-type="display-unstructured">Grozdanov L, Zähringer U, Blum-Oehler G, Brade L, Henne A, Knirel YA, Schombel U, Schulze J, Sonnenborn U, Gottschalk G, Hacker J, Rietschel ET, Dobrindt U (2002) A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 184:5912–5925 <pub-id pub-id-type="pmid">12374825</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grozdanov</surname><given-names>L</given-names></name><name><surname>Raasch</surname><given-names>C</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name><name><surname>Sonnenborn</surname><given-names>U</given-names></name><name><surname>Gottschalk</surname><given-names>G</given-names></name><name><surname>Hacker</surname><given-names>J</given-names></name><name><surname>Dobrindt</surname><given-names>U</given-names></name></person-group><article-title>Analysis of the genome structure of the nonpathogenic probiotic <italic>Escherichia coli</italic> strain Nissle 1917</article-title><source>J Bacteriol</source><year>2004</year><volume>186</volume><fpage>5432</fpage><lpage>5441</lpage><pub-id pub-id-type="doi">10.1128/JB.186.16.5432-5441.2004</pub-id></citation><citation citation-type="display-unstructured">Grozdanov L, Raasch C, Schulze J, Sonnenborn U, Gottschalk G, Hacker J, Dobrindt U (2004) Analysis of the genome structure of the nonpathogenic probiotic Escherichia coli strain Nissle 1917. J Bacteriol 186:5432–5441 <pub-id pub-id-type="pmid">15292145</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henker</surname><given-names>J</given-names></name><name><surname>Blokhin</surname><given-names>BM</given-names></name><name><surname>Bolbot</surname><given-names>YK</given-names></name><name><surname>Maydannik</surname><given-names>VG</given-names></name><name><surname>Joeres</surname><given-names>L</given-names></name><name><surname>Wolff</surname><given-names>C</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name></person-group><article-title>Successful therapy of unspecific prolonged diarrhoea in infants and toddlers with the probiotic <italic>E. coli</italic> Nissle 1917</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><fpage>A-315</fpage></citation><citation citation-type="display-unstructured">Henker J, Blokhin BM, Bolbot YK, Maydannik VG, Joeres L, Wolff C, Schulze J (2006) Successful therapy of unspecific prolonged diarrhoea in infants and toddlers with the probiotic E. coli Nissle 1917. Gastroenterology 130:A-315 </citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kruis</surname><given-names>W</given-names></name><name><surname>Fric</surname><given-names>P</given-names></name><name><surname>Pokrotnieks</surname><given-names>J</given-names></name><name><surname>Lukas</surname><given-names>M</given-names></name><name><surname>Fixa</surname><given-names>B</given-names></name><name><surname>Kascak</surname><given-names>M</given-names></name><name><surname>Kamm</surname><given-names>MA</given-names></name><name><surname>Weismueller</surname><given-names>J</given-names></name><name><surname>Beglinger</surname><given-names>C</given-names></name><name><surname>Stolte</surname><given-names>M</given-names></name><name><surname>Wolff</surname><given-names>C</given-names></name><name><surname>Schulze</surname><given-names>J</given-names></name></person-group><article-title>Maintaining remission of ulcerative colitis with the probiotic <italic>E coli</italic> Nissle 1917 is as effective as with standard mesalazine</article-title><source>Gut</source><year>2004</year><volume>53</volume><fpage>1617</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1136/gut.2003.037747</pub-id></citation><citation citation-type="display-unstructured">Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J (2004) Maintaining remission of ulcerative colitis with the probiotic E coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617–1623 <pub-id pub-id-type="pmid">15479682</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lehmacher</surname><given-names>W</given-names></name><name><surname>Wassmer</surname><given-names>G</given-names></name></person-group><article-title>Adaptive sample size calculations in group sequential trials</article-title><source>Biometrics</source><year>1999</year><volume>55</volume><fpage>1286</fpage><lpage>1290</lpage><pub-id pub-id-type="doi">10.1111/j.0006-341X.1999.01286.x</pub-id></citation><citation citation-type="display-unstructured">Lehmacher W, Wassmer G (1999) Adaptive sample size calculations in group sequential trials. Biometrics 55:1286–1290 <pub-id pub-id-type="pmid">11315085</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lodinova-Zadnikova</surname><given-names>R</given-names></name><name><surname>Sonnenborn</surname><given-names>U</given-names></name></person-group><article-title>Effect of preventive administration of a nonpathogenic <italic>Escherichia coli</italic> strain on the colonization of the intestine with microbial pathogens in newborn infants</article-title><source>Biol Neonate</source><year>1997</year><volume>71</volume><fpage>224</fpage><lpage>232</lpage></citation><citation citation-type="display-unstructured">Lodinova-Zadnikova R, Sonnenborn U (1997) Effect of preventive administration of a nonpathogenic Escherichia coli strain on the colonization of the intestine with microbial pathogens in newborn infants. Biol Neonate 71:224–232 <pub-id pub-id-type="pmid">9129791</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lodinova-Zadnikova</surname><given-names>R</given-names></name><name><surname>Tlaskalova-Hogenova</surname><given-names>H</given-names></name><name><surname>Sonnenborn</surname><given-names>U</given-names></name></person-group><article-title>Local and serum antibody response in fullterm and premature infants after artificial colonization of the intestine with <italic>E. coli</italic> strain Nissle 1917 (Mutaflor®)</article-title><source>Pediatr Allergy Immunol</source><year>1992</year><volume>3</volume><fpage>43</fpage><lpage>48</lpage></citation><citation citation-type="display-unstructured">Lodinova-Zadnikova R, Tlaskalova-Hogenova H, Sonnenborn U (1992) Local and serum antibody response in fullterm and premature infants after artificial colonization of the intestine with E. coli strain Nissle 1917 (Mutaflor®). Pediatr Allergy Immunol 3:43–48 </citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McFarland</surname><given-names>LV</given-names></name><name><surname>Elmer</surname><given-names>GW</given-names></name><name><surname>McFarland</surname><given-names>M</given-names></name></person-group><article-title>Meta-analysis of probiotics for the prevention and treatment of acute pediatric diarrhea</article-title><source>Int J Probiotics Prebiotics</source><year>2006</year><volume>1</volume><fpage>63</fpage><lpage>76</lpage></citation><citation citation-type="display-unstructured">McFarland LV, Elmer GW, McFarland M (2006) Meta-analysis of probiotics for the prevention and treatment of acute pediatric diarrhea. Int J Probiotics Prebiotics 1:63–76 </citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patzer</surname><given-names>SI</given-names></name><name><surname>Baquero</surname><given-names>MR</given-names></name><name><surname>Bravo</surname><given-names>D</given-names></name><name><surname>Moreno</surname><given-names>F</given-names></name><name><surname>Hantke</surname><given-names>K</given-names></name></person-group><article-title>The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN</article-title><source>Microbiology</source><year>2003</year><volume>149</volume><fpage>2557</fpage><lpage>2570</lpage><pub-id pub-id-type="doi">10.1099/mic.0.26396-0</pub-id></citation><citation citation-type="display-unstructured">Patzer SI, Baquero MR, Bravo D, Moreno F, Hantke K (2003) The colicin G, H and X determinants encode microcins M and H47, which might utilize the catecholate siderophore receptors FepA, Cir, Fiu and IroN. Microbiology 149:2557–2570 <pub-id pub-id-type="pmid">12949180</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sazawal</surname><given-names>S</given-names></name><name><surname>Hiremath</surname><given-names>G</given-names></name><name><surname>Dhingra</surname><given-names>U</given-names></name><name><surname>Malik</surname><given-names>P</given-names></name><name><surname>Deb</surname><given-names>S</given-names></name><name><surname>Black</surname><given-names>RE</given-names></name></person-group><article-title>Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomized, placebo-controlled trials</article-title><source>Lancet Infect Dis</source><year>2006</year><volume>6</volume><fpage>374</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(06)70495-9</pub-id></citation><citation citation-type="display-unstructured">Sazawal S, Hiremath G, Dhingra U, Malik P, Deb S, Black RE (2006) Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomized, placebo-controlled trials. Lancet Infect Dis 6:374–382 <pub-id pub-id-type="pmid">16728323</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schroeder</surname><given-names>B</given-names></name><name><surname>Duncker</surname><given-names>S</given-names></name><name><surname>Barth</surname><given-names>S</given-names></name><name><surname>Bauerfeind</surname><given-names>R</given-names></name><name><surname>Gruber</surname><given-names>AD</given-names></name><name><surname>Deppenmeier</surname><given-names>S</given-names></name><name><surname>Breves</surname><given-names>G</given-names></name></person-group><article-title>Preventive effects of the probiotic <italic>Escherichia coli</italic> strain Nissle 1917 on acute secretory diarrhea in a pig model of intestinal infection</article-title><source>Digest Dis Sci</source><year>2006</year><volume>51</volume><fpage>724</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1007/s10620-006-3198-8</pub-id></citation><citation citation-type="display-unstructured">Schroeder B, Duncker S, Barth S, Bauerfeind R, Gruber AD, Deppenmeier S, Breves G (2006) Preventive effects of the probiotic Escherichia coli strain Nissle 1917 on acute secretory diarrhea in a pig model of intestinal infection. Digest Dis Sci 51:724–731 <pub-id pub-id-type="pmid">16614995</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schröder</surname><given-names>H</given-names></name></person-group><article-title>Entwicklung der aeroben Darmflora bei Neugeborenen nach Kolonisierung mit dem <italic>E.-coli</italic>-Stamm Nissle 1917</article-title><source>Kinderarzt</source><year>1992</year><volume>10</volume><fpage>1619</fpage><lpage>1625</lpage></citation><citation citation-type="display-unstructured">Schröder H (1992) Entwicklung der aeroben Darmflora bei Neugeborenen nach Kolonisierung mit dem E.-coli-Stamm Nissle 1917. Kinderarzt 10:1619–1625 </citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulze</surname><given-names>J</given-names></name><name><surname>Lorenz</surname><given-names>A</given-names></name><name><surname>Mandel</surname><given-names>L</given-names></name></person-group><article-title>Colonization of <italic>Escherichia coli</italic> in different gnotobiotic animal models</article-title><source>Microbial Ecol Health Dis</source><year>1992</year><volume>5</volume><fpage>4</fpage><lpage>5</lpage></citation><citation citation-type="display-unstructured">Schulze J, Lorenz A, Mandel L (1992) Colonization of Escherichia coli in different gnotobiotic animal models. Microbial Ecol Health Dis 5:4–5 </citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szajewska</surname><given-names>H</given-names></name><name><surname>Mrukowicz</surname><given-names>JZ</given-names></name></person-group><article-title>Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2001</year><volume>33</volume><fpage>S17</fpage><lpage>S25</lpage><pub-id pub-id-type="doi">10.1097/00005176-200110002-00004</pub-id></citation><citation citation-type="display-unstructured">Szajewska H, Mrukowicz JZ (2001) Probiotics in the treatment and prevention of acute infectious diarrhea in infants and children: a systematic review of published randomized, double-blind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 33:S17–S25 <pub-id pub-id-type="pmid">11698781</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niel</surname><given-names>CW</given-names></name><name><surname>Feudtner</surname><given-names>C</given-names></name><name><surname>Garrison</surname><given-names>MM</given-names></name><name><surname>Christakis</surname><given-names>DA</given-names></name></person-group><article-title>Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis</article-title><source>Pediatrics</source><year>2002</year><volume>109</volume><fpage>678</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1542/peds.109.4.678</pub-id></citation><citation citation-type="display-unstructured">van Niel CW, Feudtner C, Garrison MM, Christakis DA (2002) Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. Pediatrics 109:678–684 <pub-id pub-id-type="pmid">11927715</pub-id></citation></ref></ref-list><glossary><title>Abbreviations</title><def-list><def-item><term><sc>ADDPLAN</sc></term><def><p>Adaptive Designs – Plans and Analyses</p></def></def-item><def-item><term>AE</term><def><p>adverse event</p></def></def-item><def-item><term>BMI</term><def><p>body mass index (kg/m<sup>2</sup>)</p></def></def-item><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>CPMP</term><def><p>Committee for Proprietary Medicinal Products</p></def></def-item><def-item><term>EcN</term><def><p><italic>Escherichia coli</italic> strain Nissle 1917</p></def></def-item><def-item><term>EMEA</term><def><p>European Medicines Agency</p></def></def-item><def-item><term>ICH</term><def><p>International Conference on Harmonization</p></def></def-item><def-item><term>IEC</term><def><p>Independent Ethics Committee</p></def></def-item><def-item><term>IDMC</term><def><p>Independent Data Monitoring Committee</p></def></def-item><def-item><term>ITT</term><def><p>intention to treat</p></def></def-item><def-item><term>PP</term><def><p>per protocol</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Electronic supplementary material</bold></p><p>The online version of this article (doi:http://dx.doi.org/10.1007/s00431-007-0419-x) contains supplementary material, which is available to authorized users.</p></fn><fn><p>Supported by ARDEYPHARM through the provision of verum and placebo medication and reimbursement of study-related expenditure. The authors would like to thank all hospital staff members, clinical monitors and parents for contributing to the work achieved.</p></fn></fn-group></back></article>